“David Sans, FAARM, PhD, MBA, is an accomplished healthcare and finance leader with strategic experience in healthcare and life sciences .”
David Sans, PhD, FAARM MBA, is a biotech and pharma executive with experience in corporate finance, business development, operational, and commercial roles spanning both large pharmaceutical and emerging biotechnology companies.
David Sans currently serves as Director of Healthcare at EF Hutton, where he oversees all Healthcare Transactions at EF Hutton spearheading and driving a wide range of industry transactions.
Additionally, Dr. Sans serves as a strategic advisor for the Cancer Prevention & Research Institute of Texas (CPRIT), Anixa Biosciences and the 2020 Cancer Moonshot Project.
Previously, David served as Head of Market Analytics at Pfizer during the launch of Rebif® (interferon beta-1a for MS) and Macugen® (pegaptanib) and as Sr. Medical Scientist at Novartis in Basel, Switzerland during the launch of Glivec® (imatinib), at ImClone Systems and Head of Corporate Development and David served as an Executive Officer at Mount Sinai Health Systems completing Business Development transactions with Philips, LabCorp, and Agilent. David is also a Board Member of the Lymphatic Education & Research Network in New York.
